Coradini Danila, Boracchi Patrizia, Oriana Saro, Biganzoli Elia, Ambrogi Federico
Department of Clinical Sciences and Community Health, Medical Statistics, Biometry and Bioinformatics, University of Milan, Via Vanzetti 5, Milan, 20133, Italy.
Senology Center, Ambrosiana Clinic, Cesano Boscone, Milan, 20090, Italy.
Chin J Cancer. 2015 Mar 5;34(3):121-9. doi: 10.1186/s40880-015-0004-z.
In the adult human breast, hyperplastic enlarged lobular unit (HELU) and atypical ductal hyperplasia (ADH) are two common abnormalities that frequently coexist with ductal carcinoma in situ (DCIS). For this reason, they have been proposed as the early steps in a biological continuum toward breast cancer.
We investigated in silico the expression of 369 genes experimentally recognized as involved in establishing and maintaining epithelial cell identity and mammary gland remodeling, in HELUs or ADHs with respect to the corresponding patient-matched normal tissue.
Despite the common luminal origin, HELUs and ADHs proved to be characterized by distinct gene profiles that overlap for 5 genes only. While HELUs were associated with the overexpression of progesterone receptor (PGR), ADHs were characterized by the overexpression of estrogen receptor 1 (ESR1) coupled with the overexpression of some proliferation-associated genes.
This unexpected finding contradicts the notion that in differentiated luminal cells the expression of estrogen receptor (ER) is dissociated from cell proliferation and suggests that the establishing of an ER-dependent signaling is able to sustain cell proliferation in an autocrine manner as an early event in tumor initiation. Although clinical evidence indicates that only a fraction of HELUs and ADHs evolve to invasive cancer, present findings warn that exposure to synthetic progestins, frequently administered as hormone-replacement therapy, and estrogens, when abnormally produced by adipose cells and persistently present in the stroma surrounding the mammary gland, may cause these hyperplastic lesions.
在成年女性乳房中,增生性小叶单位增大(HELU)和非典型导管增生(ADH)是两种常见的异常情况,它们常与导管原位癌(DCIS)共存。因此,它们被认为是乳腺癌生物学连续发展过程中的早期阶段。
我们通过计算机分析,研究了369个经实验证实参与建立和维持上皮细胞特性及乳腺重塑的基因,在增生性小叶单位增大或非典型导管增生组织以及与之匹配的患者正常组织中的表达情况。
尽管增生性小叶单位增大和非典型导管增生有着共同的管腔起源,但它们的基因谱却截然不同,仅有5个基因重叠。增生性小叶单位增大与孕激素受体(PGR)的过表达相关,而非典型导管增生的特征是雌激素受体1(ESR1)的过表达以及一些增殖相关基因的过表达。
这一意外发现与分化的管腔细胞中雌激素受体(ER)的表达与细胞增殖无关这一观点相矛盾,并表明建立雌激素受体依赖性信号传导能够以自分泌方式维持细胞增殖,这是肿瘤发生早期的一个事件。尽管临床证据表明只有一部分增生性小叶单位增大和非典型导管增生会发展为浸润性癌,但目前的研究结果警示,作为激素替代疗法经常使用的合成孕激素以及脂肪细胞异常产生并持续存在于乳腺周围基质中的雌激素,可能会导致这些增生性病变。